Abstract
Off-label use of drugs in pediatrics remains a national and international problem. The American Academy of Pediatrics determined in 1977, and reaffirmed in 1995, that there was a moral imperative to formally study drugs in children so they “have access to important medications and receive optimal drug therapy.” Congress passed legislation in 1997 that encouraged the study of patent drugs, or those with remaining exclusivity or patent protection, in pediatric patients. Manufacturers of new chemical entities could earn an incentive (in the form of pediatric exclusivity) for their product if a program of pediatric clinical research that met the requirements of a Written Request from the Food and Drug Administration was completed as scheduled. Such pediatric research must be expected to yield medically valuable information for pediatric patients. Additional legislation, the Best Pharmaceutical for Children Act, which renewed the exclusivity incentive for the “on-patent” drugs and provides a mechanism to facilitate the study of “off-patent drugs”, and the Pediatric Research Equity Act address ways to encourage obtaining safety and efficacy data in pediatric patients. Pediatric drug trials require a concerted effort from academia, industry and patient advocacy groups to obtain safety, efficacy, and pharmacokinetic data in placebo-controlled or active-controlled multicenter trials. Because of the unique nature of pediatric patients, data for pediatric drug labeling may need to be derived from creative clinical trial designs and population pharmacokinetic studies, randomized withdrawal trials, enrichment studies, as well as the utilization of extrapolation of clinical efficacy when appropriate. These novel approaches to clinical trial design as well as a discussion of more classical clinical trials are discussed in relation to pediatric clinical studies.
Similar content being viewed by others
References
Bodensteiner JB, Roach ES. Sturge-Weber Syndrome. Mt. Freedom, NJ: The Sturge-Weber Foundation; 1999.
Chapieski L, Friedman A, Lachar D. Psychological functioning in children and adolescents with Sturge-Weber syndrome. J Child Neurol. 2000;15:660–665.
Miller RS, Ball K, Comi AM, Germain-Lee EL. Growth hormone deficiency in children with Sturge-Weber syndrome. Arch Dis Child. Accepted.
Roberts R, Rodriguez W, Murphy D, Crescenzi T. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA. 2003;290:905–911.
Best Pharmaceuticals for Children Act, Pub. L. No. 107–109. 2002. Available at: http://frweb-gate.access.gpo.gov/hcgi-bin/useftp.cgi?IPaddress-162.140.64.21&filename-publ109.pdf&directory-/diskc/wais/data/107_cong_public_laws. Accessed September 16, 2005.
Pediatric Research Equity Act, Pub. L No. 108–155, 2003. Available at: http://frwebgate.ac-cess.gpo.gov/hcgi-bin/useftp.cgi?IPaddress-162.140.64.21&filename-publ155.pdf&directory-/diskb/wais/data/108_cong_public_laws. Accessed September 16, 2005.
Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. BMJ. 1948;(2): 769–782.
Terry TL. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens. Part I: preliminary report. Am J Ophthal. 1942;25:203–204.
Campbell K. Intensive oxygen therapy as a possible cause of retrolental fibroplasia: a clinical approach. Med J Australia. 1951;2:48–50.
Patz A. Hoeck LE, De La Cruz E. Studies on the effect of high oxygen administration in retrolental fibroplasia: nursery observations. Am J Ophthal. 1952;35:1248–1253.
Dawson B, Trapp RG. Basic and Clinical Biostatistics. New York: Lange Medical Books, McGraw-Hill; 2001.
Spilker B. Guide to Clinical Trials. New York: Raven Press; 1991.
Friedman LM, Furberg CD, DeMets, DL. Fundamentals of Qinical Trials. Boston: John Wright, PSG;1981.
Jones B, Kenward MG. Design and Analysis of Cross-Over Trials. London: Chapman and Hall; 1989.
Temple RJ. When are clinical trials of a given agent vs. placebo no longer appropriate or feasible? Controlled Clin Trials. 1997;18:613–620.
Temple RJ. Enrichment designs: efficiency in development of cancer treatments. J Clin Oncol. 2005;23:4838–4839.
Vray M, Girault D, Hoog-Labouret N, Porcher R, Thalabard JC. Methodology for small clinical trials. Therapie. 2004:59:273–286.
Temple RJ. Special study designs: early escape, enrichment, studies in non-responders. Commun Statist Theory Meth. 1994;23:499–531.
Pledger GW, Schmidt, D. Evaluation of anti-epileptic drug efficacy: a review of clinical trial design. Drugs. 1994;48:498–509.
Jonas MM, Kelley DA, Mizerski J, et al. for the International Pediatric Lamivudine Investigator Group. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med. 2002; 346:1706–1713.
Shapiro G, Bronsky E, Murray A, Barnhart F, VanderMeer A, Reisner C. Clinical comparability of Ventolin formulated with hydrofiuoroalkane or conventional chlorofluorocarbon propellants in children with asthma. Arch Pediatr Adolesc Med. 2000;154:1219–1225.
Wells T, Frame V, Softer B, et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol. 2002;42:870–880.
Biederman J, Frank A, Lopez FA, Boellner SW, Chandler MC. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics. 2002:110:258–266.
Glauser TA, Nigro M, Sachdeo R, et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. Neurology. 2000;54:2237–2244.
Author information
Authors and Affiliations
Corresponding author
Additional information
The Drug Information Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Drug Information Association designates this educational activity for a maximum of 1 category I credit toward the AMA Physician’s Recognition Award. Each physician should only claim those credits that he/she actually spent in the activity.
lf you would like to receive a statement of credit, you must review the article. answer the questions to the posttest on the Post-test and Evaluation Form and submit it to the DIA. Participants must receive a passing score of 80% or better on the post-test in order to receive a statement of credit. Statements of credit will be mailed within one month of receipt of the Post-test and Evaluation Form. There is no fee to receiveyour statement of credit.
Rights and permissions
About this article
Cite this article
McCune, S.K., Mathis, L.L., Cocchetto, D.M. et al. Safer, Better, More Appropriate: Clinical Trial Design for Pediatric Drug Labels. Ther Innov Regul Sci 40, 185–195 (2006). https://doi.org/10.1177/009286150604000207
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286150604000207